 And I'll leave it to you on the order. Thank you very much for introducing us from Japan. As you see, three representatives has come to this important conference from the government and from the national project and from the university. I'm now co-comer a counselor at the Cabinet Secretary of the Japanese government. I'm not a scientist, unfortunately, but as the national officials. And in charge of promoting new initiative for medical research, all over the medical research. Today, we have three topics. First topic, which I will explain, is national medical new policy. And the second topic to be presented by Dr. Kubo is national genomic medicine project. Following his topic, Dr. Miyano will talk about project implemented by the University of Tokyo. After five years has passed since Mr. Abe left the prime minister's position, he came back, he recaptured government last year. And soon after, he formed his new cabinet. He declared three pillars of stability. One is the broad monetary policy. And the second one was the flexible fiscal policy. And the third one was the economic growth strategy. One of the key policy issues regarding the growth strategy is medical and healthcare policy. Yes. In Japan, the government used to promote medical research and development through three ministries. Ministry of Health, Labor and Welfare, Ministry of Education, Cultural, Sports, Science and Technology, and Ministry of Economy, Trade and Industry. However, as you can see, this is the new structure to promote the national medical research and development policy in Japan. We've established these all structure last year. In order to achieve practical use of national medical research, Prime Minister Abe decided to integrate all the medical R&D budget under the leadership of the Cabinet Secretary. This budget should be allocated upon the prioritized field by the decision of the headquarter in accordance with the strategic policy for the medical research. The government is now also preparing for the blue one, the blue one, a new independent administrative agency. This new agency shall manage all the related activities in the field of medical research. The older budget will be allocated centrally by this new agency. We intend all the national project to cover from basic to practical use seamlessly. As a result of the huge political initiative, the budget for the fiscal year to 2014 increases about 20% from the former year. One of the key component of the cooperation project is listed here, there are nine. One of them is genetic medicine, the last one on the left side. The total budget for the same is about seven billion yen, which is approximately 70 million US dollar. This page shows the brief idea of the cooperative project toward realizing genomic medicine. The government coordinate not only basic program and the research infrastructure, but also clinical research on the left side in a single and comprehensive view in order to achieve clinical application. For this purpose, we had advocated several goals to be achieved toward the 2015 or 2020 or 2030. From the beginning stage. Okay, now from this place, I should pass that microphone to the specialist national and the leader of the national project, Dr. Kubo, please. Thank you very much. And I'll briefly overview of this genetic medicine project in Japan. And the aim of this project improved medical care and healthcare for common diseases, including cancer and left side-related disease by using the implementation of the genetic medicine. So based on the health and medical strategy by the Japanese government, this project promotes clinical application of the genetic research finding for the aiming at the return to the public and in parallel with the strengthening of the genetic research infrastructure. So this project has three parts. One, the first is on the left side in the construction of the Biobank network. Using the useful Biobank network, central genome center in the middle position will perform the large-scale genetic research and to build the comprehensive the genetic variation database that linked to the clinical phenotypes such as the disease suspicility or the drug responses. And if we get the genetic variation database, medical genome center will perform the clinical research by using the genetic information to validate the efficacy and the cost effectiveness of the genetic information in the clinical setting. And so that the medical genome center will establish the optimized treatment through the prediction of drug responses and optimization of the predictive diagnostics and optimization of the preventive healthcare. So I will talk in the Biobank network and Dr. Miyano will talk about the supercomputer facility in the central genome center and also the other activities in the Tokyo University. I want to first show you the Biobank Japan project. This project was started in 2003 as a leading project of the MEX. In the first period of the five years, we collected 47 target diseases in patients DNA, serum and clinical information and constructed the Biobank Japan including these are the numbers of the patients. And using these samples, we performed large scale GWAS and identified many suspected genes for various diseases and drug responses. And in the third period from the last year, we further extend the research infrastructure of the Biobank Japan and also promote the genetic research. The second Biobank is a national center Biobank network that was recently developed by the cooperation of the six national centers including Geriat diseases, cardiovascular diseases and general medicine, cancer center, childhood disease and neuropsychiatric diseases. They are now collecting samples and making the catalog databases and the important thing is huge number of tissue collections in this Biobank. And the third one is the Tohoku Medical Megabank. As you know that Japan has a great East Asian earthquake in three years ago, then this project was started as one of the recovery project. The objectives of this project is revitalization of the medical care in the disaster area and develop infrastructure for next generation medicine. This project will perform the health survey in 150 cells on individuals in the disaster area and construct Biobank and analyze to do the genomic analysis for the aiming at the drug discovery or the personalized medicine. So I will move to the next person. Well thank you. The Institute of Medical Science of the University of Tokyo locates in the center of Tokyo and it is in 10 minutes to the Super Express train station and in 30 minutes to the Tokyo Haneda Airport. Location is very fine. And in that campus around 1000 people are working and the team of the Human Genome Center, the Advanced Clinical Research Center and the Research Hospital with 135 beds and the supercomputer system is involved with our genomic medicine practice. And this supercomputer system will be used by the end of this year. We will have a new one next year, next January. And the usage is limited to genomic and biological sciences, not for physics. And it's important, its performance is currently 225 telephrops, it has 22,000 CPU cores and the storage system is a three petabyte high-speed parallel disk array and two petabyte normal disk system in total five petabyte storage. And annual budget is about 10 million US dollar. And the genomic medicine started at IMS in 2001 by focusing on specific genes in the small scale as shown in this slide. And the patients and the clients are cancer, hereditary diseases, common diseases, and the genetic issues. The team of genetic medicine is collaborating with the Japanese Association of Hospitals for Genetic Medicine and the Tokyo Genetic Counseling Network. And the follow-up and surveillance of genetic counseling has been provided and it has a history of 13 years. And by the drastic advancement of sequencing technologies such as silicon chip-based sequencing to cope with the near future genomic medicine, we are now extending this system to whole genome sequencing more. The LC team was directed by Kaori Muto and the genetic counseling team is directed by Yoichi Furukawa. And at the hospital, clinical sequence covers cancer and blood disorders due to limited expertise. And the whole genome clinical sequence is currently as a part of research. And we recognize the bottleneck of the system is data analysis and clinical interpretation. And the more serious problem is lack of specialists who can do this task. Decision support system and effective use of biomedical big data will be a very important key to our practice. And this is part of the sequence and the data analysis facilities and the supercomputer there was already installed and most equipment are placed in this secure network system. And the genetic and the genomic information is separated from the medical record by the policy. And for sequencing technology, we are waiting for nanopore sequencing or without the nanopore sequencing. And the last sentence is the University of Tokyo University of Tokyo is founding the International Genomic Medicine Research Organization by participating in two research institutions and two graduate schools. One is School of Medicine. Thank you very much. One question about this, particularly this last piece where you're obviously generating an enormous amount of research data. But on the right hand side, you anticipate clinical applications and I'm wondering what process you have in place to make the decision about when something gets released from research and put into clinical practice. Well, it's a headache, actually. Tell us something we don't know. Yeah, Frank Ray speaking. We would characterize it as a major headache but I think we're on the same page. I was wondering if you could, could you put the slide back up please? Could you talk more about the International Genomic Medicine Research Organization? I know we were a little late on time. The last slide. Just in terms of, yes. So you're founding that, what do you envision that to be? I'm thinking about that from the perspective of how that, which has international in it, would interface with what we're trying to do here and where there might be some synergies. Yeah, but the international means, this is within the University of Tokyo but the collaborating with some international universities, we have not specified it, but candidates are raised. So you're forming it at the top? Yes, right. Truly, not domestic I mean. Not closed within Japan, oh well. It's a good question, the, yeah. She is a, she is a kind of boss in a very high place and she is whipping us to install these kind of things and make proposal to fit the idea, yeah. I have been writing a proposal every year, yeah. But failed, but new initiative started. I do hope the such international organization to collaborate internationally will be created. I do hope. Thank you for support. Well, I want to thank all of you. Ms. Okamura, Dr. Kubo, Dr. Miano, thank you for your presentation and a great note to end on for the day. We have still one more item to cover as we wrap up.